180161-17-5

Basic information

• Product Name: 4-(2-FLUOROPHENYL)PIPERIDINE
• Synonyms: 4-(2-FLUOROPHENYL)PIPERIDINE;OTAVA-BB 1287667
• CAS NO: 180161-17-5
• Molecular Formula: C₁₁H₁₄FN
• Molecular Weight: 179.2339632
• Mol File: 180161-17-5.mol

Chemical Properties

• Boiling Point: 242.9 °C at 760 mmHg
• Flash Point: 100.7 °C
• Appearance: /
• Density: 1.048 g/cm³
• Vapor Pressure: 0.033mmHg at 25°C
• Refractive Index: 1.506
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-(2-FLUOROPHENYL)PIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-FLUOROPHENYL)PIPERIDINE(180161-17-5)
• EPA Substance Registry System: 4-(2-FLUOROPHENYL)PIPERIDINE(180161-17-5)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 180161-17-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-(2-Fluorophenyl)piperidine is used as a chemical precursor for the synthesis of various medications, primarily due to its potential role in creating antipsychotic and analgesic drugs. Its unique structure allows for the development of compounds that can interact with specific biological targets, offering new avenues for the treatment of mental health disorders and pain management.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 4-(2-Fluorophenyl)piperidine serves as a key component in the design and synthesis of novel psychoactive substances. Its unique properties, including the presence of the fluorine atom, can influence the pharmacokinetics and pharmacodynamics of the resulting compounds, potentially leading to the discovery of new therapeutic agents with improved efficacy and safety profiles.
Used in Drug Development:
4-(2-Fluorophenyl)piperidine is utilized in drug development as a building block for creating new pharmaceutical entities. Its structural features can be fine-tuned to optimize the drug-like properties of the compounds derived from it, such as solubility, stability, and bioavailability, which are crucial for the success of a drug candidate in clinical trials and eventual market approval.

InChI:InChI=1/C11H14FN/c12-11-4-2-1-3-10(11)9-5-7-13-8-6-9/h1-4,9,13H,5-8H2

Upstream product

• 694-05-3 1,2,3,6-tetrahydropyridine 
• 462-06-6 fluorobenzene 
• 1993-03-9 o-fluorophenylboronic acid 
• 138647-49-1 4-Trifluoromethanesulfonyloxy-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 1121057-69-9 tert-butyl 4-(2-fluorophenyl)-5,6-dihydropyridine-1(2H)-carboxylate 

Downstream Products

• 180157-62-4 (2S)-(-)-1-(4-indolyloxy)-3-(4-(2-fluorophenyl)piperidin-1-yl)-2-propanol ethanedioate 
• 1034592-64-7 C₂₉H₂₃Cl₂FN₄O 
• 1207865-22-2 C₂₉H₂₅Cl₂FN₄O₂ 
• 1400928-27-9 C₂₅H₃₀FN₃O₂ 
• 1254980-15-8 8-(trifluoromethyl)-3-(cyclopropylmethyl)-7-[(4-(2-fluorophenyl)-1-piperidinyl)methyl]-1,2,4-triazolo[4,3-a]pyridine 
• 1175689-41-4 (6-chloro-pyridin-2-yl)-[4-(2-fluoro-phenyl)-piperidin-1-yl]-methanone 

Relevant articles and documents

20-HETE FORMATION INHIBITORS

This disclosure provides novel heterocyclic compounds and methods for inhibiting the enzyme CYP4. Further disclosed methods include: a method of inhibiting the biosynthesis of 20-hydroxyeicosatetraenoic acid (20-HETE) in a subject in need thereof and a method of producing neuroprotection and decreased brain damage by preventing cerebral microvascular blood flow impairment and anti-oxidant mechanisms in a subject experiencing or having experienced an ischemic event.

Design, synthesis and evaluation of substituted piperidine based KCNQ openers as novel antiepileptic agents

Epilepsy is a kind of disease with complicated pathogenesis. KCNQ (Kv7) is a voltage dependent potassium channel that is mostly associated with epilepsy and thus becomes an important target in the treatment of epilepsy. In this paper, a series of substituted piperidine derivatives targeting KCNQ were designed and synthesized by using scaffold hopping and active substructure hybridization. Compounds were evaluated by fluorescence-based thallium influx assay, Rb+ flow assay and electrophysiological patch-clamp assay. Results showed that some compounds possessed more potent potassium channel opening activity than Retigabine. More significantly, compound 11 was found to have good pharmacokinetic profiles in vivo.

Superacid-catalyzed preparation of aryl-substituted piperidines via dicationic electrophiles

The electrophilic chemistry of 1,2,3,6-tetrahydropyridines has been studied in the Bronsted superacid, CF3SO3H (triflic acid). The 1,2,3,6-tetrahydropyridines react with arenes to give aryl-substituted piperidines. It is proposed tha